Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,400 preclinical stage partnering deals announced since 2016 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of preclinical stage deal making since 2016. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.
Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 25 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2016, where a contract document is available in the public domain.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2016.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2016.
In addition, a comprehensive appendix of all preclinical deals since 2016 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Insight into the terms included in a preclinical stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 includes:
- Trends in preclinical stage dealmaking in the biopharma industry since 2016
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,400 preclinical stage deals
- The leading preclinical stage deals by value since 2016
- Most active preclinical stage dealmakers since 2016
- The leading preclinical stage partnering resources
In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive access to available deals and contract documents for over 2,400 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,400 preclinical stage deals together with contract documents if available
- Detailed access to actual preclinical stage deals entered into by the leading big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Identify leading preclinical stage deals by value since 2016
- Identify the most active preclinical stage dealmakers since 2016
- Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 – Introduction
Chapter 2 – Why do companies partner preclinical stage compounds?
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals
Chapter 3 – Preclinical stage deal strategies and structure
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
22.214.171.124. Discovery and preclinical stage partnering case studies
126.96.36.199.a. Case study 1
188.8.131.52.b. Case study 2
184.108.40.206.c. Case study 3
220.127.116.11.d. Case study 4
3.2.2. Partnering later in pharmaceutical/biotech
18.104.22.168. Clinical stage partnering case studies
22.214.171.124.a. Case study 5
126.96.36.199.b. Case study 6
188.8.131.52.c. Case study 7
184.108.40.206.d. Case study 8
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study 9
3.6.1.b. Case study 10
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study 11
3.7.1.b. Case study 12
Chapter 4 – Preclinical stage partnering payment strategies
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
220.127.116.11. Conditionality of upfront payments
4.3.4. Convertible loans
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
18.104.22.168. Issues affecting royalty rates
22.214.171.124. Royalties on combination products
126.96.36.199.a. Case study 13
188.8.131.52. Guaranteed minimum/maximum annual payments
184.108.40.206. Royalty stacking
220.127.116.11. Royalties and supply/purchase contracts
4.3.11. Option payments
Chapter 5 – Trends in preclinical stage deal making
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2016
Chapter 6 – Payment terms for preclinical stage partnering
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates
Chapter 7 – Leading preclinical stage deals
7.2. Top preclinical stage deals by value
Chapter 8 – Top 25 most active preclinical stage dealmakers
8.2. Top 25 most active preclinical stage dealmakers
Chapter 9 – Preclinical stage partnering contracts directory
9.2. Preclinical stage deals with contracts 2014 to 2021
Chapter 10 – Preclinical stage deal making by development stage
10.2. Deals by preclinical stage
Appendix 1 – Preclinical stage dealmaking by companies A-Z
Appendix 2 – Preclinical stage dealmaking by industry sector
Appendix 3 – Preclinical stage dealmaking by stage of development
Appendix 4 – Preclinical stage dealmaking by therapy area
Appendix 5 – Preclinical stage dealmaking by technology type
About Wildwood Ventures
Recent titles from Current Partnering
Table of figures
Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for preclinical stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Preclinical stage partnering frequency 2016 - 2023
Figure 6: Preclinical stage partnering by deal type since 2016
Figure 7: Preclinical stage partnering by disease type since 2016
Figure 8: Preclinical stage partnering by technology type since 2016
Figure 9: Top 25 most active preclinical stage dealmakers, 2016 to 2023
Figure 10: Review of upfront payments for preclinical stage deals
Figure 11: Review of milestone payments for preclinical stage deals
Figure 12: Review of royalty payments for preclinical stage deals
Figure 13: Preclinical stage deals with a headline value
Figure 14: Preclinical stage deals with an upfront value
Figure 15: Preclinical stage deals with a milestone value
Figure 16: Preclinical stage deals with a royalty rate value
Figure 17: Top preclinical stage deals by value since 2016
Figure 18: Most active preclinical stage dealmakers 2016 to 2023
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
1ST Biotherapeutics, 2A, 2cureX, 3B Pharmaceuticals, 3DMed, 3D Medicines, 3rd People’s Hospital of Shenzhen, 4basebio Discovery, 4C Biomed, 4D Molecular Therapeutics, 4E Therapeutics, 4P-Pharma, 4SC, 7 Hills Pharma, 9 Meters Biopharma, 23andMe, 180 Life Sciences, A*STAR Agency for Science, Technology and Research, A2 Biotherapeutics, Aadi Bioscience, Aarhus University, Aarvik Therapeutics, AB Biosciences, Abbott Laboratories, Abbott Vascular Devices, Abbvie, AbClon, Abdul Latif Jameel Health, Ab E Discovery, Abeona Therapeutics, Abera Bioscience, AbFero Pharmaceuticals, Abide Therapeutics, ABL Bio, Abmuno Therapeutics, Abound Bio, Abpro, AbSci, ABT Innovations, ABVC BioPharma, Abzena, Academy of Military Medical Sciences (China), ACADIA Pharmaceuticals, AC Bioscience, Acceleron Pharma, Accure Therapeutics, ACEA Therapeutics, Acepodia, Aceragen, Acer Therapeutics, Acetylon Pharmaceuticals, Achaogen, Ache, Achieve Life Science, AC Immune, Aclipse Therapeutics, Actelion, Acticor Biotech, Actimed Therapeutics, Actinium Pharmaceuticals, Acucela, Acuitas Therapeutics, AcuraStem, Acurx Pharmaceuticals, AdAlta, Adalvo, Adaptimmune, AdaptVac, Adcendo, ADC Therapeutics, Addex Therapeutics, Adge Pharmaceuticals, Adhera Therapeutics, Adial Pharmaceuticals, Adimab, Adjuvance Technologies, Adlai Nortye, Advaccine Biotechnology, Advanced Accelerator Applications, Advanced Biological Laboratories, Advanced BioScience Laboratories, Advanced Regenerative Manufacturing Institute, Advaxis, Aelis Pharma, Aerie Pharmaceuticals, Aevi Genomic Medicine, AffaMed Therapeutics, Affigen, Affilogic, Affimed Therapeutics, AGC Biologics, Ageless Biotech, Agenus Bio, AgeX Therapeutics, Agilvax, Agios Pharmaceuticals, AgomAb Therapeutics, AgonOx, AiCuris, AIkido Pharma, Aimed Bio, AIM ImmunoTech, AIMM Therapeutics, Aimmune Therapeutics, Aion Therapeutic, Airway Therapeutics, Ajinomoto, Ajinomoto Bio-Pharma Services, Akaal Pharma, Akari Therapeutics, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, AKL Research and Development, Akouos, Akoya Biosciences, AKSO Biopharmaceutical, Akston Biosciences, Albany Molecular Research, Alberta Cell Therapy Manufacturing, Alchemab, Alder Biopharmaceuticals, Alderley Analytical, Aldevron, Aldeyra Therapeutics, Alector, Alectos Therapeutics, Aleta Biotherapeutics, Alexion Pharmaceuticals, Algae-C, Algenex, Algernon Pharmaceuticals, Aligos Therapeutics, AliveGen, Alivio Therapeutics, Alkahest, Alkermes, Allarity Therapeutics, Allergan, Alliance for Cancer Gene Therapy, Alligator Bioscience, Allist Pharma, Allogene Overland Biopharm, Allogene Therapeutics, AllStripes, Alma Bio Therapeutics, Almirall, Alnylam Pharmaceuticals, Alopexx, Alphamab Biopharmaceuticals, Alpha Tau Medical, Alpine Immune Sciences, ALS Association, Altasciences, Altesa Biosciences, Altimmune, Alto Neuroscience, Altor BioScience, ALTuCELL, Alume Biosciences, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Ambiopharm, Ambrx, American National Multiple Sclerosis Society, Amerimmune, Amgen, Amicus Therapeutics, AmideBio, Amneal Pharmaceuticals, Amolyt Pharma, Amorsa Therapeutics, Ampio Pharmaceuticals, AmpliPhi Biosciences, Amryt Pharma, Amunix, Amylgen, Amyris, AnaBios, Angany, AnGes MG, Angiex, AnHeart Therapeutics, Anika Therapeutics, Anima Biotech, Animal Life Sciences, Anixa Biosciences, Annovis Bio, Anokion, ANP Technologies, Antengene, Anterios, Anthos Therapeutics, AntibioTx, Antidote Therapeutics, Antios Therapeutics, Antoxerene, Apic Bio, Apollomics, Apollon Formularies, Appello Pharmaceuticals, Appili Therapeutics, Applied Biology, Applied BioMath, Applied DNA Sciences, Applied Genetic Technologies, Applied Nanoscience, Aprea, AprilBio, APRINOIA Therapeutics, Aptahem, Aptar Pharma, Aptevo Therapeutics, Aptinyx, Aptorum Group, Aptose Biosciences, Aqualung Therapeutics, Aquinnah Pharmaceuticals, Aragen Bioscience, Aratana Therapeutics, Aravive Biologics, Arbor Biosciences, Arbor Biotechnologies, Arbutus, ArcherDX, ARC Therapeutics, Arctic Therapeutics, Arctic University of Norway, Arctic Vision, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, Ardena, Arecor, Arena Pharmaceuticals, AREV Life Sciences, argenx, Aridis Pharmaceuticals, Arix Bioscience, Arizona State University, AroCell, Aromics, Array Biopharma, Arrevus, ArriVent Biopharma, Arrowhead Pharmaceuticals, Arrys Therapeutics, Arsanis Biosciences, Artelo Biosciences, ArtemiLife, Artes Biotechnology, Artios Pharma, Artiva Biotherapeutics, Artizan Biosciences, Asahi Kasei, Ascentage Pharma, Asep Medical, Asher Biotherapeutics, Ashvattha Therapeutics, AskAt, Asklepios Biopharmaceutical, Aslan Pharma, Assembly Biosciences, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astellas Pharma US, Astellas Venture Management, AstraZeneca, Astrogen, Asylia Therapeutics, Asymchem Laboratories, Atara Biotherapeutics, Atbtherapeutics, Atelerix, Ateria Health, Athenex, Athersys, Atonco, Atreca, Attralus, ATUM, aTyr Pharma, Audentes Therapeutics, Augmenta, AUM Biosciences, AUM Biotech, AUM LifeTech, Aurealis Therapeutics, Aurelius Biotherapeutics, Aurigene Discovery Technologies, Aurinia Pharmaceuticals, AusHealth, Austrian Research Promotion Agency, Autifony Therapeutics, Autotelic BIO, Avacta, Avania, Avectas, AVEO Oncology, Avery Therapeutics, AveXis, Avicanna, Avid Bioservices, AVM Biotechnology, Avrobio, Axelys, Axovant Gene Therapies, Ayala Pharmaceuticals, Aytu BioPharma, Bach Biosciences, Bachem, Baergic Bio, Banner MD Anderson Cancer Center, Barbara Ann Karmanos Cancer Institute, Barer Institute, Barrow Neurological Institute, Barth Syndrome Foundation, Bascom Palmer Eye Institute, Batavia Biosciences, Bateman Horne Center, Baxalta, Bayer, Baylor College of Medicine, BayMedica, BB100, Beacon Discovery, Beactica, Beam Therapeutics, BeiGene, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, Bellicum Pharmaceuticals, Benitec Biopharma, Beroni Group, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Betta Pharmaceuticals, Beyond Batten Disease Foundation, BGI, BGN Technologies, Bharat Biotech, Bial, Bill and Melinda Gates Foundation, Bio-Techne, BioAesthetics, BioAge Labs, BioAgilytix, BioAnalytical Systems, Bioarchitech, BioArctic Neuroscience, BioArdis, biOasis Technologies, BioAtla, BioAxone BioSciences, BioAxone Therapeutic, BioCanRx, BioCentriq, Bioceros, Biocon, BioCorRx, BioCryst Pharmaceuticals, BioCure, Biocytogen, Biodesix, Biodextris, BioEleven, Biogen, BioGeneration Ventures, Bioharmony Therapeutics, Biohaven Pharmaceuticals, BioInvent, BioIVT, BioKey, BioLamina, BiolineRX, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), BioMed X Innovation Center, Biomica, BioMotiv, Biomunex Pharmaceuticals, BiomX, Bionaut Labs, Biond Biologics, BiondVax, Bionomics, BioNova Pharmaceuticals, BioNTech, Bionure, Biopharmaceuticals Australia, Bioscience Pharma Partners, Biose Industrie, Biosion, BioSpring, Biotheus, Biotools, BioVaxys, Bioventure MDC, Bioventus, BioVersys, BioVie, BirchBioMed, Bird Foundation, BJ Bioscience, Blackstone, Blackstone Medical, Blau Pharma, Bloom Science, Bluebird Bio, BlueJay Therapeutics, Blueprint Medicines, BlueRock Therapeutics, Blue Water Vaccines, BlueWillow Biologics, Boehringer Ingelheim, Bohai Biomedical, Bold Therapeutics, Bolt Biotherapeutics, Bone Therapeutics, Bonnie J. Addario Lung Cancer Foundation, Boryung Pharmaceutical, Boston Pharmaceuticals, Boston Scientific, Boston University, BoyaLife, Bpifrance, BriaCell Therapeutics, BrickBio, Brickell Biotech, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrighGene Biomedical, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Brown University, BryoLogyx, Bugworks, Burning Rock, Butantan Institute, C-Bridge Capital, C4 Therapeutics, C4X Discovery, Cabaletta Bio, Cadent, Cadila Pharmaceuticals, Calico, Calidi Biotherapeutics, Califia Pharma, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calithera Biosciences, Calvert Laboratories, Calvert Research, Calypso Biotech, Camargo Pharmaceutical Services, Cambrian Biopharma, Camurus, Can-Fite BioPharma, Canada-Israel Industrial R&D Foundation, Canadian Institutes of Health Research, CANbridge Pharmaceuticals, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CancerVax, Candel Therapeutics, Cannabics Pharmaceuticals, Cannex Scientific, Cannomed Medical Cannabis Industries, Cantargia, Capricor Therapeutics, CARB-X, Cardiovascular Solutions of Central Mississippi, Cardurion Pharmaceuticals, Carina Biotech, Caris Life Sciences, Carisma Therapeutics, Carna BioSciences, CaroGen, CARsgen, Cascade Chemistry, Cascadian Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, Castle Creek Biosciences, Catabasis Pharmaceuticals, Catalent, Catalyst Biosciences, Catholic University Leuven, CB Therapeutics, CBT Pharmaceuticals, Cedars-Sinai Medical Center, Cedilla Therapeutics, Celator, Celgene, Cell and Gene Therapy Catapult, CellBion, Cellectar Biosciences, Cellect Biotechnology, Cellectricon, Cellerant Therapeutics, Cellevolve Bio, Cell Medica, Cell Mogrify, Cell Point, Cell Therapy Catapult, Celltrion, Cellular Biomedicine, Cellumed, Cellusion, Celmatix, Celonic, Cel Sci, Celularity, Celyad, Censo Biotechnologies, Centers for Disease Control and Prevention, Centivax, Centogene, Centre for Addiction and Mental Health, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Human Drug Research, Centre for Probe Development and Commercialization, Centre For The Commercialization Of Antibodies And Biologics, Centrexion, Century Therapeutics, Cerecor, CereHealth, CERIMED, Certis, Cerveau Technologies, Cevec Pharmaceuticals, cGMP Validation, Champions Oncology, Changchun BCHT Biotechnology, Charcot-Marie-Tooth Association, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Cheil Pharm, Chembio Diagnostics, Chemomab Therapeutics, Chemveda Life Sciences, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital of Philadelphia, Chimeron Bio, China Medical System, Chinook Therapeutics, ChromaDex, Chroma Therapeutics, Chronos Therapeutics, Chrysalis BioTherapeutics, Chugai Pharmaceutical, Ciitizen, CimCure, Cincinnati Children’s Hospital Medical Center, Cingulate, Cipher Pharmaceuticals, Cirqle Biomedical, Citius Pharmaceuticals, City College of New York, City of Hope, CiVi Biopharma, Clarivate Analytics, Clarus Therapeutics, Clearmind Medicine, Cleave Therapeutics, Clene Nanomedicine, Cleveland Clinic, Click Therapeutics, Clinical Laserthermia Systems (CLS), Clinica Universidad Navarra, Clinton Health Access Initiative, Clover Biopharmaceuticals, Clovis Oncology, CMAB Biopharma, CMC Biologics, CNS Pharmaceuticals, Coalition for Epidemic Preparedness Innovations, Coave Therapeutics, Cobra Biologics, Cochin Hospital, Cochlear, Cocrystal Pharma, Codagenix, Codexis, Codiak BioSciences, Coeptis Pharmaceuticals, Coeptis Therapeutics, Cofactor Genomics, Cognate BioServices, Cognition Therapeutics, CohBar, Coherus Biosciences, CoImmune, Colibri Heart Valve, Colorado State University, Columbia Technology Ventures, Columbia University, Columbia University Medical Center, Colzyx, CombiGene, Complix, Concept Life Sciences, Confo Therapeutics, ConserV Bioscience, ConsortiaTX, Constance Therapeutics, ContraFect, ConverGene, Cook Biotech, COPD Foundation, Copenhagen University Hospital, Copernicus Therapeutics, Corbus Pharmaceuticals, Cord Blood Registry, CoreBiome, Coronado Biosciences, Cortexyme, Corvidia Therapeutics, Cosmo Bio, COUR Pharmaceutical, Covance, Covar Pharmaceuticals, CreaGen Biosciences, Creative Biolabs, Crescendo Bioscience, Crestone Pharma, Critical Path Institute (C-Path), Crohn's and Colitis Foundation of America, Cronos Group, Crossbeta Biosciences, Crown Bioscience, Crozet BioPharma, CRT Pioneer Fund, CryoPort, CrystalGenomics, CSIRO, CSL, CSL Behring, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cullinan MICA, Cullinan Oncology, Cumulus Oncology, Curacle, Curadev Pharma, Curative Biotechnology, CureCell, Cure Network Dolby Acceleration Partners, CureVac, Curia, Curis, CVC, Cyagen Biosciences, Cyan Bio, Cybin, Cybrexa Therapeutics, Cyclacel Pharmaceuticals, Cyclica, Cynata Therapeutics, Cypralis, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cyteir Therapeutics, Cytiva, CytoAgents, Cytocom, Cytokinetics, CytomX Therapeutics, Cytos Biotechnology, CytoSorbents, CytoVale, Cytovance Biologics, Cytovant Sciences, Cytovation, CYTOVIA Therapeutics, Cyxone, D. Western Therapeutics Institute, Daiichi Sankyo, Dalhousie University, Dalton Pharma Services, Dana-Farber Cancer Institute, Danish Cancer Society Research Center, Danish Innovation Fund, Danuo Science Group, Dare Bioscience, DarwinHealth, Debiopharm, Decibel Therapeutics, Deerfield Management, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Defymed, Deinove, Delix Therapeutics, Delphi Genetics, DelSiTech, DeMelle OncoPharma, Denali Therapeutics, Dendreon, Denovo Biopharma, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, DePuy, Dermelix Biotherapeutics, Dermira, DeuteRx, DevPro Biopharma, Dewpoint Therapeutics, Diaccurate, Dialectic Therapeutics, Diamond Therapeutics, Dianomi Therapeutics, Diaprost, Dicerna Pharmaceuticals, Diffusion Pharmaceuticals, Digestome Therapeutics, Dimension Therapeutics, DiNAQOR, DiNonA, DiosCURE Therapeutics, Disc Medicine, Diverchim, Diverse Biotech, dMed Biopharmaceuticals, DNX Biopharmaceuticals, Dogma Therapeutics, Dong-A ST, DoubleRainbow Biosciences, Dow Pharmaceutical Sciences, Dr. Falk Pharma, Dragonfly Therapeutics, Drug Innovation Ventures at Emory, Drugs for Neglected Diseases Initiative, DSM, Dual Therapeutics, Duke-NUS Graduate Medical School Singapore, Duke University, Duke University Medical Center, Dyadic International, Dynacure, Dyna Therapeutics, Dynavax Technologies, DynPort Vaccine Company, DZNE German Center for Neurodegenerative Diseases, Eagle Pharmaceuticals, Ecole Polytechnique de Montreal, Edesa Biotech, Edison Oncology, Editas Medicine, Eikonizo Therapeutics, Eikonoklastes Therapeutics, Eirion Therapeutics, Eisai, Elanco, ELIAS Animal Health, Elicio Therapeutics, Eligo Bioscience, EligoChem, Eli Lilly, Ellipses Pharma, Elpiscience, ElsaLys Biotech, EMD Serono, Emergent BioSolutions, Emergex Vaccines, Emmaus Life Sciences, Emory University, Emulate, ENA Respiratory, Endeavor BioMedicines, Endevica Bio, Endotherm, Enesi Pharma, Enigma Biomedical, Enlivex, Ennaid Therapeutics, Enochian Biosciences, Enosi Therapeutics, Ensysce Biosciences, Entasis Therapeutics, Enterome Bioscience, Enterprise Therapeutics, Entheon Biomedical, Entos Pharmaceuticals, Entrada Therapeutics, ENYO Pharma, Enzolytics, Enzychem Lifesciences, Enzyvant Science, EOC Pharma, EpicentRx, Epigen Biosciences, Epilepsy Foundation (EF), EpimAb Biotherapeutics, Epivax, EpiVax Therapeutics, Epsilogen, Epygen Biotech, Equilibre BioPharmaceuticals, Equillium, Erasca, Erasmus University Medical Center, Erytech, Escient Pharmaceuticals, EspeRare Foundation, Essex Bio-Technology, ES Therapeutics, Eterna Therapeutics, Eternygen, Ethris, Eucure Biopharma, EuMentis Therapeutics, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Eurostars, Eureka Therapeutics, Eurocine Vaccines, Eurofins Discovery, European Commission, European Innovation Council, European Investment Bank, European Union, Eutilogics, Evax, Evecxia, Evelo Biosciences, Everest Medicines, Eversana, Evgen Pharma, Evolve BioSystems, Evommune, Evotec, Ewha Womans University, Exact Therapeutics, ExCellThera, Excelra, Exelixis, Exeltis, Exicure, ExonanoRNA, Exonate, Exopharm, Exothera, Experimental Drug Development Centre, Expesicor, ExpreS2ion Biotechnologies, Exuma Biotech, Eyam Vaccines and Immunotherapeutics, EyeMedics, Eyenovia, Eyevance, F-Star Therapeutics, F1 Oncology, Facit, Fapon Biopharma, Farmacore Biotechnology, Faron Pharmaceuticals, Fast Forward, Fatro, Federal Ministry of Education and Research (BMBF), Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, Felix Biotechnology, FerGene, Ferring Pharmaceuticals, Fibriant, Fibrocell Science, Fibrocor Therapeutics, Fibrogen, FibroGenesis, FightMND, Fimbrion Therapeutics, Find Therapeutics, Five Prime Therapeutics, Flame Biosciences, Flexion Therapeutics, FloDesign Sonics, Florida International University, Florida State University, Flow Pharma, FluGen, FLX Bio, Fondation Cancer, Food and Drug Administration (FDA), Forbion Capital Partners, Forbius, Foresite Capital, Forge Biologics, Forge Therapeutics, FORMA Therapeutics, Formula Pharmaceuticals, Fortify Therapeutics, Fortress Biotech, Forty Seven, Fosun Pharmaceutical, Foundation Fighting Blindness, Foundation for Biomedical Research and Innovation, FoxBio, Fox Chase Cancer Center, Frazier Healthcare Ventures, Fred Hutchinson Cancer Research Center, Frequency Therapeutics, FSD Pharma, Fuhong Hanlin, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm Diosynth Biotechnologies, Fulgent Pharma, Fusion Pharmaceuticals, G-Tech Bio, G1 Therapeutics, G3 Pharmaceuticals, GACI Global, Galapagos, Galmed Pharmaceuticals, Gamida Cell, Gannex Pharma, GB Sciences, GC Pharma, Gem Pharma, GEn1E Lifesciences, GeneCentric Therapeutics, GeneCraft, Genelux, Genentech, GeneQuantum Healthcare, GeneQuine Biotherapeutics, Generex Biotechnology, Genethon, Genetic Immunity, GeneTx Biotherapeutics, GeNeuro, Genevant Sciences, Genezen, Genmab, Gennova Biopharmaceuticals, Genocea Biosciences, Genomic Health, Genomma Lab Internacional, Genprex, GenScript Biotech, GenScript ProBio, GenStem Therapeutics, George Mason University, Georgetown University, George Washington University, Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Red Cross, Gesynta Pharma, Gibson Oncology, Giiant Pharma, Gilead Sciences, Ginkgo BioWorks, Glaukos, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Global Antibiotic Research and Development Partnership, Global Blood Therapeutics, Global Cancer Technology, Global TransBiotech, Glycotope Biotechnology, Glympse Bio, Glythera, Glytherix, GNP Bioscience, Golden Mountain Partners, Goldfinch Bio, Government of Australia, Government of Canada, Government of Netherlands, GPCR Therapeutics, Gracell Biotechnologies, Gradalis, Grail, Graphite Bio, Great Bay Bio, Green Cross LabCell, Greenlight Biosciences, Greenr U, Greenwich LifeSciences, Grey Wolf Therapeutics, Griffith University, Gritstone Bio, Group K Diagnostics, GT Biopharma, GTP Bioways, Guangzhou Boji Medical Biotechnological, Gubra, GW Pharmaceuticals, Gyroscope Therapeutics, Hackensack Meridian Health, Hadasit Medical Research Services and Development, Hadassah Medical Center, HaemaLogiX, Halozyme Therapeutics, Hamlet Pharma, HanAll Pharmaceuticals, Hande Sciences, Hangzhou Zhongmei Huadong Pharmaceutical, Hansa Biopharma, HanX Biopharmaceuticals, Harbour Biomed, Harpoon Therapeutics, Harvard Medical School, Harvard University, Havn Life Sciences, Hawaii Biotech, HCW Biologics, HD Biosciences, HDT Bio, Healion Bio, Healios K.K., Heartseed, Heidelberg Pharma, Hemera Biosciences, Hemogenyx, HemoShear, Henlius Biotech, Henry Ford Health System, Henry M. Jackson Foundation, Hepion Pharmaceuticals, Herantis, HiberCell, HiFiBio, HilleVax, Hillhurst Biopharmaceuticals, Hillstream BioPharma, Histogen, Hisun BioRay, HitGen, Hoffmann La Roche, Hope Medicine, Horama, Horizon Discovery, Horizon Europe, Horizon Therapeutics, Hoth Therapeutics, HSRx Group, Huadong Medicine, Hualan Genetic, Humanetics, Humanigen, Hummingbird Bioscience, Huyabio International, HUYA Bioscience, Hybridize Therapeutics, Hybridyne Imaging Technologies, Hyloris Pharmaceuticals, Hypersomnia Foundation, I-mab, IACTA Pharmaceuticals, IAMA Therapeutics, Iaso Therapeutics, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, Iconovo, IDEAYA Biosciences, Idorsia, IDT Biologika, IGAN Biosciences, IGM Biosciences, Igyxos, Iksuda Therapeutics, Iktos, Ildong Pharmaceutical, Illumina, ImageIQ, Imanis Life Sciences, ImCheck Therapeutics, Imcyse, Imeka, Immatics Biotechnologies, Immodulon Therapeutics, Immune Biosolutions, ImmuneOncia Therapeutics, Immune System Regulation, Immune Therapeutics, ImmuNext, Immunic, ImmunityBio, ImmunoBiochem, Immunocore, ImmunoFlex, ImmunoForge, ImmunoGen, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPhotonics, ImmunoPrecise Antibodies, ImmunoQure, ImmunoScape, ImmunoTek Bio Centers, Immuron, ImmVira, Imperial College London, Imperial Innovations, ImQuest BioSciences, Imugene, In4Derm, Incannex Healthcare, Inception Sciences, Incyte, Indapta Therapeutics, Indiana University, Indian Institute of Science Education and Research, Indica Labs, Indivior, Inexia, Infectious Disease Research Institute (IDRI), Infex Therapeutics, InflamaCORE, Inflection Biosciences, Inhalation Sciences, Inhalon Biopharma, Inhibikase Therapeutics, Inhibrx, Initiator Pharma, Inmagene Biopharmaceuticals, InMed Pharmaceuticals, INmune Bio, Innate Pharma, Innoforce Pharmaceuticals, Innovate Biopharmaceuticals, Innovate UK, Innovation Norway, Innovation Pharmaceuticals, Innovent Biologics, Inotrem, Inoviem Scientific, Inovio Pharmaceuticals, Inozyme Pharma, Insilico Biotechnology, Insilico Medicine, Insmed Inc, InSphero, Inspyr Therapeutics, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute for Life Changing Medicines, Institute for Molecular Medicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for the Promotion of Innovation by Science and Technology in Flanders, Institute of Endocrinology, Metabolism, and Reproduction, Institute of Hematology and Blood Transfusion, Institut Gustave Roussy, Institut Pasteur, Intarcia Therapeutics, Intec Pharma, Integral Molecular, Integrated BioTherapeutics, Intellia Therapeutics, International Vaccine Institute (IVI), Interpace Diagnostics, Intravacc, iNtRON Biotechnology, IntuitiveX, Inventiva, Inventprise, Invetx, Ionetix, Ionis Pharmaceuticals, Iovance Biotherapeutics, IOVaxis Therapeutics, ipCapital Group, I Peace, Ipsen, IQVIA, Ironwood Pharmaceuticals, ISD Immunotech, IsoPlexis, Isoprene Pharmaceuticals, IsoTherapeutics, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Istari Oncology, iTolerance, Itus, iVeena Delivery Systems, Iveric Bio, Ivy Brain Tumor Center, Ixaka, Ix Therapeutics, J-STAR Research, Jackson Laboratory, Jadi Cell, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jasper Therapeutics, Javelin Biotech, Jazz Pharmaceuticals, JCR Pharmaceuticals, jCyte, Jefferson Healthcare, Jellagen, Jemincare, Jenner Institute, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu NHWA Pharmaceutical, Jiangsu Qyun Bio-Pharmaceutical, Jiangsu QYuns Therapeutics, Ji Xing Pharmaceuticals, Johannes Gutenberg University, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Johnson Matthey, Jounce Therapeutics, JSC Pharmadis, JSR, Jubilant Biosys, Jubilant Radiopharma, Jubilant Therapeutics, Juniper Biologics, Juno Therapeutics, Junshi Biosciences, Juntendo University, Just Biotherapeutics, Juvena Therapeutics, Juvenescence, Juvenile Diabetes Research Foundation, Juventas Therapeutics, JW Pharmaceutical, JW Therapeutics, Kadmon Pharmaceuticals, KAHR Medical, Kainos Medicines, Kaken Pharmaceutical, KaliVir Immunotherapeutics, KalVista Pharmaceuticals, Kalytera Therapeutics, Kamada, Kanaph Therapeutics, Kane Biotech, KangWon University Institute of Medical Science, Kantaro Biosciences, Kanyr Pharma, Karolinska Development, Karolinska Institute, Karuna Therapeutics, Karyopharm Therapeutics, Kashiv BioSciences, Kazia Therapeutics, KBI BioPharma, KDAc Therapeutics, Keck School of Medicine of USC, Kedrion Biopharma, Keio Gijuku University, Kelai Pharmaceuticals, KemPharm, Kemwell BioPharma, Kennedy Institute of Rheumatology, Kentucky Organ Donor Affiliates, Kenya Medical Research Institute, Khon Kaen University, Kiadis Pharma, Kindred Bio, Kineta, Kinetic Concepts, Kings College London, Kiniksa Pharmaceuticals, Kinnate Biopharma, Kinnear Pharmaceuticals, KinoPharma, Kinoxis Therapeutics, Kintara Therapeutics, Kintor, Kiq, Kiromic Biopharma, Kiyatec, Kleo Pharmaceuticals, Knight Cancer Institute, Knight Therapeutics, Knopp Biosciences, Kolltan Pharmaceuticals, Kolon Life Science, Konkuk University, Korea-Israel Industrial R&D Foundation, Kovina Therapeutics, Kriya Therapeutics, Kronos Bio, KSQ Therapeutics, Kubota Vision, Kuria Therapeutics, Kuros Biosciences, KYAN Therapeutics, Kyn Therapeutics, Kyorin Pharmaceutical, Kyttaro, Kyverna Therapeutics, L'Oreal, LabCentral, Laboratoires Thea, Laboratory Corporation of America, Lactiga, Laekna, La Jolla Institute for Allergy & Immunology, Lamassu Pharma, LamKap Bio Group, Lantern Pharma, La Paz Hospital, Launch Therapeutics, Laurel Therapeutics, Laurel Venture Capital, Lauren Sciences, Lava Therapeutics, Lawrence Livermore National Laboratory, Leap Therapeutics, Lee's Pharmaceutical, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Leiden University, Leidos, LEITAT, Lenire Biosciences, Lentigen, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, Leukocare, LeukoCom, LEXEO Therapeutics, LGC, LG Life Sciences, LianBio, Liechti Lab, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Light Chain Bioscience, Lighthouse Pharmaceuticals, LimmaTech Biologics, Lin Bioscience, Lineage Cell Therapeutics, LineaRx, LinKinVax, Linnaeus Therapeutics, Linus Oncology, LiteVax, Live Like Bella Childhood Cancer Foundation, Livzon Mabpharm, Lobe Sciences, Lobesity Pharma, Locana, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, London School of Medicine and Dentistry, Longevity Biotech, Lonza, Louisiana State University, Loxo Oncology, LSU Health Sciences Center, Lubeck Institute of Experimental Dermatology, Lucid Psycheceuticals, Luminary Therapeutics, Lundbeck, Lund University, Lung Biotechnology, Lupagen, Lupin Limited, Lupin Pharmaceuticals, Lupus Foundation of America (LFA), Luxcel Biosciences, Luxembourg National Research Fund, LyGenesis, Lyndra Therapeutics, Lysogene, Lysosomal Therapeutics, Lytica Therapeutics, Lytix Biopharma, Maastricht University, MAB Discovery, MabVax Therapeutics, Mabwell Bioscience, Macrogenics, Macromoltek, Macrostruct Holding & Consulting, Magenta Therapeutics, MagicMed Industries, MAIA Biotechnology, Maine Medical Center, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, MangoGen Pharma, Manhattan BioSolutions, Mannin Research, MannKind Biopharmaceuticals, MapKure, Mapp Biopharmaceutical, Marinomed Biotechnologie, Maruho, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, Mateon Therapeutics, Matinas Biopharma, MatriSys Bioscience, MaveriX Oncology, Mawson Infrastructure, Max-Planck, Maxcyte, Mayo Clinic, McGill University, McMaster University, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, MDA Venture Philanthropy, MDimune, MDNA Life Sciences, Meabco, Mebias Discovery, Medac, Medicago, Medical & Biological Laboratories (MBL), Medical College of Wisconsin, Medical Research Council, Medical University of Graz, Medical University of South Carolina, Medical University of Vienna, Medicines Discovery Catapult, MediciNova, Medifocus, MediGene, Medigen Vaccine Biologics, MedImmune, Mediolanum, Medison Pharma, Medivir, MediWound, Medpace, MedPharm, Medytox, Meitheal Pharmaceuticals, Melior Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Merck and Co, Merck KGaA, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus, Mesoblast, Metaclipse Therapeutics, Metacrine, Metagenomi, MetasTx, Metrion Biosciences, MetVital, Metys Pharmaceuticals, Michael J Fox Foundation, Michigan State University, Microbion, Microbiotica, Microbiotix, MicroCures, Micron Biomedical, MicroQuin, Millar, Millennium, MilliporeSigma, MiMedx, MimiVax, Minaris Regenerative Medicine, MiNA Therapeutics, Mind Medicine, Mindset Pharma, MindShift Compounds, MinervaX, Minoryx Therapeutics, Minotaur Therapeutics, miRagen Therapeutics, Mirati Therapeutics, Mironid, Mirum Pharmaceuticals, Mission Bio, Mitacs, Mitochon Pharmaceuticals, Mitokinin, MITRO Biotech, Mochida Pharmaceutical, Moderna, Modus Therapeutics, MolecularMD, Molecular Partners, Molecular Templates, Moleculin Biotech, Molnlycke Health Care, Mologen, Momenta Pharmaceuticals, Monopar Therapeutics, MorphoSys, Mosanna Therapeutics, Mount Sinai Health System, Mount Sinai Medical Center, mProbe Laboratories, MRIGlobal, Multiple Myeloma Research Foundation, Multitude Therapeutics, Murdoch Childrens Research Institute, Muscular Dystrophy Association, Mustang Bio, MyBiotics Pharma, Mycenax Biotech, Mylan Pharmaceuticals, MyMD Pharmaceuticals, Mymetics, MYM Nutraceuticals, MyoKardia, Myonexus Therapeutics, MYOS, Myosana Therapeutics, Myovant Sciences, Myrtelle, Naason Science, Nacuity Pharmaceuticals, NanoBio, Nanobiotix, Nanoform, Nanomerics, Nanotherapeutics, NaNotics, NanoTx Therapeutics, NanoViricides, Nanovis, NantBioScience, NantKwest, NantVentures, NantWorks, Nanyang Technological University, NASA, Nascent Biotech, Natera, National Cancer Center, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health, National Centre for Research and Development, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes for Quantum and Radiological Science and Technology, National Institutes of Health, National Jewish Health, National Research Council Canada, National Research Council of Canada, National Resilience, National Science Foundation, National Stem Cell Foundation, National University Hospital, National University of Ireland, Galway (NUI Galway), National University of Singapore, Nationwide Children’s Hospital, Natural Sciences and Engineering Research Council of Canada, Naval Medical Research Center, Navidea Biopharmaceuticals, Navigo Proteins, Navrogen, NBE Therapeutics, Nektar Therapeutics, Nencki Institute, NeoDynamics, Neo Gene Pharm, Neogene Therapeutics, Neomed Institute, Neon Therapeutics, Neos Therapeutics, Neovacs, NervGen Pharma, Nestle Health Science, Netherlands Cancer Institute, NeuCen BioMed, NeuCyte, NeuExcell, Neumora Therapeutics, NeurAegis, NeuralStem, Neuraly, Neuraxpharm, Neurgain Technologies, NeurMedix, NeuroBo Pharmaceuticals, Neurochase, Neurocrine Biosciences, NeuroCycle Therapeutics, Neurolixis, NeuroLucent, Neuron-Experts, Neurophth Therapeutics, Neuropore Therapies, NeuroTrauma, NeuroVive Pharmaceutical, NeuRx Pharmaceuticals, Neuway Pharma, NewCanna Hub, Newsoara Biopharma, New York Blood Center, New York Presbyterian/Columbia, New Zealand's Foundation for Research, Science and Technology, Nexel, Neximmune, NextCure, NEXT Oncology, NFL Biosciences, Nicox, Nightstar Therapeutics, Nihon Medi-Physics, NiKang Therapeutics, Nimbus Therapeutics, NIMIUM Therapeutics, Ningbo NewBay Medical Technology, Ningbo Tai Kang Medical Technology, Nitrome Biosciences, NJCTTQ, NKGen Biotech, NKMax America, NLC Pharma, Noachis Terra, Nobelpharma, Noema Pharma, Noile-Immune Biotech, Nordic Bioscience, North Carolina State University, Northeastern University, Northern Biologics, Northern Biomedical Research, NorthShore University HealthSystem, NorthStar Medical Radioisotopes, NorthX Biologics, Norwegian Research Council, Nosopharm, Novan, Novan Therapeutics, NovaRock Biotherapeutics, Novartis, Novartis Institute for Tropical Diseases, Novasep, Novavax
For full list of comapnies please contact us on firstname.lastname@example.org
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.